• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

Gemcabene Inhibitor

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5753181

Gemcabene is a first-in-class lipid-lowering agent. It shows lowers low-density lipoprotein cholesterol (LDL-C) and decreases triglycerides. It also raises HDL-C and lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP), exerting… More details

Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
Gemcabene, Inhibitor
Full Product Name
Gemcabene
Product Synonym Names
PD-72953
Form/Format
Solid. Powder
Purity/Purification
98.00%
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
Molecular Weight
302.41
Solubility
DMSO: 125mg/mL (413.35mM)
(<1mg/ml refers to the product slightly soluble or insoluble)
Formula
C16H30O5
SMILES
O=C(O)C(C)(C)CCCCOCCCCC(C)(C)C(O)=O
CAS Number
183293-82-5
Target & IC50
Others

Structure of Gemcabene, inhibitor

Gemcabene Inhibitor – Cat# MBS5753181

Product References and Citations for Gemcabene, inhibitor

Mandema JW, et al. Model-based development of gemcabene, a new lipid-altering agent. AAPS J. 2005 Oct 7;7(3):E513-22.
Mandema JW, et al. Model-based development of gemcabene, a new lipid-altering agent. AAPS J. 2005 Oct 7;7(3):E513-22.
Srivastava RAK, et al. Gemcabene, a First-in-Class Hypolipidemic Small Molecule in Clinical Development, Attenuates Osteoarthritis and Pain in Animal Models of Arthritis and Pain. Front Pharmacol. 2018 May 11;9:471.
Srivastava RAK, et al. Gemcabene, a First-in-Class Hypolipidemic Small Molecule in Clinical Development, Attenuates Osteoarthritis and Pain in Animal Models of Arthritis and Pain. Front Pharmacol. 2018 May 11;9:471.
Oniciu DC, et al. Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM model of NASH. PLoS One. 2018 May 30;13(5):e0194568.
Oniciu DC, et al. Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM model of NASH. PLoS One. 2018 May 30;13(5):e0194568.

Other Notes

Small volumes of Gemcabene, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Gemcabene purchase

MBS5753181 is an inhibitor targeting Gemcabene.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000